Eric Dobmeier
Director/Board Member at STRUCTURE THERAPEUTICS INC.
Net worth: 284 048 $ as of 2024-05-30
Profile
Eric L.
Dobmeier is currently the President, Chief Executive Officer & Director at Chinook Therapeutics U.S., Inc. He is also an Independent Director at Structure Therapeutics, Inc. Previously, Mr. Dobmeier held the position of President & Chief Executive Officer at Silverback Therapeutics, Inc. in 2018.
He also served as the Chairman, President & Chief Executive Officer at Chinook Therapeutics, Inc. from 2020 to 2023.
Additionally, he was the President & Chief Executive Officer at Silverback Therapeutics, Inc. and an Independent Director at Stemline Therapeutics, Inc. from 2012 to 2018.
Mr. Dobmeier was a Director at Versartis, Inc. from 2017 to 2018 and an Independent Director at Adaptive Biotechnologies Corp.
from 2016 to 2021.
He also served as an Independent Director at Atara Biotherapeutics, Inc. from 2015 to 2024.
Prior to that, he was the Chief Operating Officer at Seagen Inc. from 2014 to 2018.
Mr. Dobmeier's education includes an undergraduate degree from Princeton University and a graduate degree from Berkeley Law University of California.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-14 | 506,325 ( 0.42% ) | 284 048 $ | 2024-05-30 | |
| 2024-06-24 | 0 ( -.--% ) | - $ | 2024-05-30 |
Eric Dobmeier active positions
| Companies | Position | Start |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Director/Board Member | 2022-11-30 |
Chinook Therapeutics U.S., Inc.
 Chinook Therapeutics U.S., Inc. Information Technology ServicesTechnology Services Chinook Therapeutics U.S., Inc. operates as a development stage company. The company is headquartered in Seattle, WA. | Chief Executive Officer | - |
Former positions of Eric Dobmeier
| Companies | Position | End |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Director/Board Member | 2024-06-09 |
| CHINOOK THERAPEUTICS, INC. | Chief Executive Officer | 2023-08-10 |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Director/Board Member | 2021-03-16 |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Director/Board Member | 2018-10-11 |
| STEMLINE THERAPEUTICS, INC. | Director/Board Member | 2018-06-20 |
Training of Eric Dobmeier
| Princeton University | Undergraduate Degree |
| Berkeley Law University of California | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Health Technology |
| STRUCTURE THERAPEUTICS INC. | Commercial Services |
| Private companies | 9 |
|---|---|
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Venture Law Group
 Venture Law Group Miscellaneous Commercial ServicesCommercial Services Venture Law Group provided law and legal services. The firm specialized in mergers and acquisitions, bankruptcy and restructuring, taxation, labor and employment, intellectual property, technology licensing, corporate partnerships, and executive compensation. The company was founded in 1993 and is headquartered in Menlo Park, CA. | Commercial Services |
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
Heller Ehrman LLP
 Heller Ehrman LLP Miscellaneous Commercial ServicesCommercial Services Heller Ehrman LLP provides legal services. It offers litigation, business, and intellectual property services. The company was founded in 1980 and is headquartered in San Francisco, CA. | Commercial Services |
Versartis, Inc.
Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
Silverback Therapeutics, Inc.
 Silverback Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Silverback Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The company was founded by Peter A. Thompson January 4, 2016 and is headquartered in Seattle, WA. | Health Technology |
Chinook Therapeutics, Inc. /Old/
 Chinook Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Chinook Therapeutics, Inc operates as a biotechnology company, which engages in the development of medicines for kidney diseases. The company is headquartered in Vancouver, Canada. | Commercial Services |
Chinook Therapeutics U.S., Inc.
Chinook Therapeutics U.S., Inc. Information Technology ServicesTechnology Services Chinook Therapeutics U.S., Inc. operates as a development stage company. The company is headquartered in Seattle, WA. | Technology Services |
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Eric Dobmeier
